Michael Moore and Biotech

Selected healthcare news for the person - Michael Moore, and the healthcare topic - Biotech. We have 17 shared news items for this connection to-date.

Please provide a valid email address.
Michael Moore Shares Healthcare News With (link):
Healthcare Topics
Companies
Health Systems

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/13/2020 Oncolytics Biotech® to Present at the RBC Global Healthcare Conference PR Newswire SAN DIEGO and CALGARY, Alberta , May 13, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey , President & CEO of Oncolytics Biotech, will present ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications 858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors 212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
5/8/2020 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders PR Newswire SAN DIEGO and CALGARY, Alberta , May 8, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech Inc ...
4/30/2020 Oncolytics Biotech® Announces Changes to Annual General Meeting PR Newswire SAN DIEGO and CALGARY, Alberta , April 30, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), (the " Company ") today announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
4/18/2020 Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic PR Newswire SAN DIEGO, California and CALGARY, Alberta , April 17, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on the potential impact of COVID-19 ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications 858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors 212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
4/2/2020 Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer PR Newswire SAN DIEGO and CALGARY, Alberta , April 2, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced positive clinical data published in a peer-reviewed journal highlighting ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +1-858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc. Related ...
3/17/2020 Coronavirus for All ... Michael Moore says that the public health-types in government tell him that he’s right. In Boston, Biogen ’s name will forever be mud. One of the high-flying executives of the successful biotech corporation contracted the coronavirus somewhere other than Boston. They then brought it to the hotel conference room and, afterward, to the restaurant/bar, where (through those handshakes and hugs), in a soon-to-be-famous superspreader ...
3/5/2020 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights PR Newswire SAN DIEGO and CALGARY, Alberta , March 5, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and ... laws. Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg Company Contact Michael Moore Investor Relations & Corporate Communications 858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors 212.915.2564 [email protected] SOURCE Oncolytics Biotech® Inc. Related ...
2/28/2020 Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights PR Newswire SAN DIEGO and CALGARY, Alberta Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
1/27/2020 Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma PR Newswire SAN DIEGO and CALGARY, Alberta , Jan. 27, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
1/22/2020 Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer PR Newswire SAN DIEGO and CALGARY, Alberta , Jan. 22, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the previously announced abstract for a poster to be ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech® Inc ...
1/13/2020 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma PR Newswire SAN DIEGO and CALGARY, Alberta , Jan. 13, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader call ... looking statements, except as required by applicable laws. Company Contact Michael Moore Investor Relations & Corporate Communications +858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +212-915-2564 [email protected] SOURCE Oncolytics Biotech Inc ...
1/9/2020 Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma PR Newswire SAN DIEGO and CALGARY, Alberta , Jan. 9, Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion ... laws. Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg Company Contact Michael Moore Investor Relations & Corporate Communications +1-858-886-7813 [email protected] Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-212.915.2564 [email protected] SOURCE Oncolytics Biotech, Inc. Related ...
11/13/2019 Oncolytics Biotech Inc. (ONCY) CEO Dr. Matt Coffey on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha Seeking Alpha Oncolytics Biotech Inc. (NASDAQ: ONCY ) Q3 2019 Earnings Conference Call November 00, 2019 05:00 PM ET Company Participants Michael Moore - VP of IR & Corporate Communications Dr. Matt Coffey - President, CEO Kirk Look - CFO Andrew de Guttadauro - Global Head of Business Development Conference Call Participants John Newman - Canaccord Wangzhi Li - Ladenburg Jerry Isaacson - Roth Capital Operator Good day, ladies and gentlemen. My name is Kat and I’ll be your conference operator ...
9/26/2019 Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors | Markets Insider Business Insider ... Michael Moore , Chairman of Macrophage Pharma, said: "On behalf of the Board I am pleased to welcome Anker as an independent director who has developed an outstanding reputation for having founded and built several successful companies within the European biotech sector. As MPL evolves into the next stage of its development Anker will prove a valuable resource in the translation of the products of our proprietary Esterase Sensitive Motif™ (ESM ...
9/26/2019 Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors | Markets Insider Business Insider ... Michael Moore , Chairman of Macrophage Pharma, said: "On behalf of the Board I am pleased to welcome Anker as an independent director who has developed an outstanding reputation for having founded and built several successful companies within the European biotech sector. As MPL evolves into the next stage of its development Anker will prove a valuable resource in the translation of the products of our proprietary Esterase Sensitive Motif™ (ESM ...
9/26/2019 Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors PR Newswire ... Michael Moore , Chairman of Macrophage Pharma, said: "On behalf of the Board I am pleased to welcome Anker as an independent director who has developed an outstanding reputation for having founded and built several successful companies within the European biotech sector. As MPL evolves into the next stage of its development Anker will prove a valuable resource in the translation of the products of our proprietary Esterase Sensitive Motif™ (ESM ...
6/6/2019 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) | Seeking Alpha Seeking Alpha Oncolytics Biotech, Inc. (NASDAQ: ONCY ) Oncolytics Co-Development Agreement Call June 5, 2019 8:30 AM Michael Moore – Vice President-Investor Relations and Corporate Communications Matt Coffey – President and Chief Executive Officer Andrew de Guttadauro – President-Oncolytics Biotech U.S. and Global Head of Business Development Kirk Look – Chief Financial Officer John Newman – Canaccord Genuity Wangzhi Li – Ladenburg Thalmann Tom Shrader – BTIG Chad Messer – Needham & Company Doug Loe – Echelon Wealth Partners Operator ...